Prognostic associations of circulating phytoestrogens and biomarker changes in long-term survivors of postmenopausal breast cancer

References

• Adlercreutz H: Lignans and human health. Crit Rev Clin Lab Sci. 2007;44:483–525.
   PubMed Web of Science ®Google Scholar
• Grace PB, Mistry NS, Carter MH, Leathem AJ, Teale P. High throughput quantification of phytoestrogens in human urine and serum using liquid chromatography/tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853:138–146.
   PubMed Web of Science ®Google Scholar
• Knasmüller S. Krebs und Ernährung: Risiken und Prävention – wissenschaftliche Grundlagen und Ernährungsempfehlungen. Stuttgart: Thieme; 2014.
   Google Scholar
• Buck K, Zaineddin AK, Vrieling A, Linseisen J, Chang-Claude J. Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am J Clin Nutr. 2010;92:141–153.
   PubMed Web of Science ®Google Scholar
• Chen M, Rao Y, Zheng Y, Wei S, Li Y, Guo T, Yin P. Association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-analysis of epidemiological studies. PLoS One. 2014;9:e89288.
   PubMed Web of Science ®Google Scholar
• Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat. 2011;125:315–323.
   PubMed Web of Science ®Google Scholar
• Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst. 2006;98:459–471.
   PubMed Web of Science ®Google Scholar
• Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 2008;98:9–14.
   PubMed Web of Science ®Google Scholar
• Seibold P, Vrieling A, Johnson TS, Buck K, Behrens S, Kaaks R, Linseisen J, Obi N, Heinz J, Flesch-Janys D, et al. Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis. Int J Cancer. 2014;135:923–933.
   PubMed Web of Science ®Google Scholar
• Chi F, Wu R, Zeng Y-C, Xing R, Liu Y, Xu Z-G. Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studies. Asian Pac J Cancer Prev. 2013;14:2407–2412.
   PubMedGoogle Scholar
• Fink BN, Steck SE, Wolff MS, Britton JA, Kabat GC, Gaudet MM, Abrahamson PE, Bell P, Schroeder JC, Teitelbaum SL, et al. Dietary flavonoid intake and breast cancer survival among women on Long Island. Cancer Epidemiol Biomarkers Prev. 2007;16:2285–2292.
   PubMed Web of Science ®Google Scholar
• McCann SE, Thompson LU, Nie J, Dorn J, Trevisan M, Shields PG, Ambrosone CB, Edge SB, Li H-F, Kasprzak C, et al. Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat. 2010;122:229–235.
   PubMed Web of Science ®Google Scholar
• Linseisen J, Rohrmann S. Biomarkers of dietary intake of flavonoids and phenolic acids for studying diet-cancer relationship in humans. Eur J Nutr. 2008;47:60–68.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Mateos A, Vauzour D, Krueger CG, Shanmuganayagam D, Reed J, Calani L, Mena P, Del Rio D, Crozier A. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update. Arch Toxicol. 2014;88:1803–1853.
   PubMed Web of Science ®Google Scholar
• Guglielmini P, Rubagotti A, Boccardo F. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. Breast Cancer Res Treat. 2012;132:661–668.
   PubMed Web of Science ®Google Scholar
• Olsen A, Christensen J, Knudsen KEB, Johnsen NF, Overvad K, Tjønneland A. Prediagnostic plasma enterolactone levels and mortality among women with breast cancer. Breast Cancer Res Treat. 2011;128:883–889.
   PubMed Web of Science ®Google Scholar
• Jaskulski S, Jung AY, Behrens S, Johnson T, Kaaks R, Thöne K, Flesch-Janys D, Sookthai D, Chang-Claude J. Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: assessment of mediation by inflammatory markers. Int J Cancer. 2018;143:2698–2708.
   PubMed Web of Science ®Google Scholar
• Kyrø C, Hansen L, Frederiksen K, Nørskov NP, Bach Knudsen KE, Eriksen AK, Holm M, Tjønneland A, Olsen A. Pre-diagnostic plasma enterolactone concentrations and breast cancer prognosis among postmenopausal women – The Danish Diet, Cancer and Health cohort. Clin Nutr. 2018;37:2217–2225.
   PubMed Web of Science ®Google Scholar
• Ellsworth RE, Valente AL, Shriver CD, Bittman B, Ellsworth DL. Impact of lifestyle factors on prognosis among breast cancer survivors in the USA. Expert Rev Pharmacoecon Outcomes Res. 2012;12:451–464.
   PubMed Web of Science ®Google Scholar
• Vijayvergia N, Denlinger CS. Lifestyle factors in cancer survivorship: where we are and where we are headed. J Pers Med. 2015;5:243–263.
   PubMed Web of Science ®Google Scholar
• Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer. 2008;123:933–941.
   PubMed Web of Science ®Google Scholar
• Labmaster. Labmaster Enterolactone TR-FIA Kit insert. Labmaster TR-FIA Research Reagents for the Measurement of Enterolactone TURKU, Finland: Labmaster, 1999 [Accessed 2019 March 14]. http://www.labmaster.fi/index.php?cat=3&action=doDownload&dl_file=kRElstzA.
   Google Scholar
• Labmaster. Labmaster Genistein TR-FIA Kit insert. Labmaster TR-FIA Research Reagents for the Measurement of Genistein TURKU, Finland: Labmaster, 1999 [Accessed 2019 March 14]. http://www.labmaster.fi/index.php?cat=3&action=doDownload&dl_file=t0XMYArj.
   Google Scholar
• Adlercreutz H, Wang GJ, Lapcík O, Hampl R, Wähälä K, Mäkelä T, Lusa K, Talme M, Mikola H. Time-resolved fluoroimmunoassay for plasma enterolactone. Anal Biochem. 1998;265:208–215.
   PubMed Web of Science ®Google Scholar
• Wang GJ, Lapcík O, Hampl R, Uehara M, Al-Maharik N, Stumpf K, Mikola H, Wähälä K, Adlercreutz H. Time-resolved fluoroimmunoassay of plasma daidzein and genistein. Steroids. 2000;65:339–348.
   PubMed Web of Science ®Google Scholar
• Waters G. H. Xevo TQ-XS. 2018. [Accessed 2019 March 16]. http://www.waters.com/waters/de_DE/Xevo-TQ-XS-Triple-Quadrupole-Mass-Spectrometry/nav.htm?cid=134889751&locale=de_DE.
   Google Scholar
• Waters G. H. Xevo TQ-S micro. 2018. [Accessed 2019 March 16]. http://www.waters.com/waters/de_DE/Xevo-TQ-S-micro-Triple-Quadrupole-Mass-Spectrometry/nav.htm?cid=134798856&locale=de_DE.
   Google Scholar
• Grace PB, Taylor JI, Botting NP, Fryatt T, Oldfield MF, Al-Maharik N, Bingham SA. Quantification of isoflavones and lignans in serum using isotope dilution liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2003;17:1350–1357.
   PubMed Web of Science ®Google Scholar
• Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol. 2008;167:653–666.
   PubMed Web of Science ®Google Scholar
• Dane AD, Hendriks MMWB, Reijmers TH, Harms AC, Troost J, Vreeken RJ, Boomsma DI, van Duijn CM, Slagboom EP, Hankemeier T, et al. Integrating metabolomics profiling measurements across multiple biobanks. Anal Chem. 2014;86:4110–4114.
   PubMed Web of Science ®Google Scholar
• Van Houwelingen, HC. Dynamic prediction by landmarking in event history analysis. Scand J Stat. 2007;34:70–85.
   Web of Science ®Google Scholar
• Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107:309–330.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Hikichi M, Ushimado K, Sugioka A, Kiriyama Y, Kuroda M, Utsumi T. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival. Clin Transl Oncol. 2017;19:1232–1240.
   PubMed Web of Science ®Google Scholar
• Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239–241.
   Web of Science ®Google Scholar
• Therneau TM, Grambsch P. Modeling survival data: extending the cox model (statistics for biology and health). New York: Springer; 2001.
   Google Scholar
• Kleinbaum D, Kupper L, Nizam A, Rosenberg E. Applied regression analysis and other multivariable methods. 5th ed. Boston, MA: Cengage Learning; 2013.
   Google Scholar
• Fontein DBY, Klinten Grand M, Nortier JWR, Seynaeve C, Meershoek-Klein Kranenbarg E, Dirix LY, van de Velde CJH, Putter H. Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial. Ann Oncol. 2015;26:1254–1262.
   PubMed Web of Science ®Google Scholar
• Bolvig AK, Kyrø C, Nørskov NP, Eriksen AK, Christensen J, Tjønneland A, Knudsen KEB, Olsen A. Use of antibiotics is associated with lower enterolactone plasma concentration. Mol Nutr Food Res. 2016;60:2712–2721.
   PubMed Web of Science ®Google Scholar
• Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W. Soy food intake and breast cancer survival. JAMA. 2009;302:2437–2443.
   PubMed Web of Science ®Google Scholar
• Kang X, Zhang Q, Wang S, Huang X, Jin S. Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ. 2010;182:1857–1862.
   PubMed Web of Science ®Google Scholar
• Nechuta SJ, Caan BJ, Chen WY, Lu W, Chen Z, Kwan ML, Flatt SW, Zheng Y, Zheng W, Pierce JP, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 2012;96:123–132.
   PubMed Web of Science ®Google Scholar
• Guha N, Kwan ML, Quesenberry CP, Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. 2009;118:395–405.
   PubMed Web of Science ®Google Scholar
• Mensink GBM, Lage Barbosa C, Brettschneider AK. Verbreitung der vegetarischen Ernährungsweise in Deutschland. J Health Monit. 2016;1:2–15. doi:10.17886/RKI-GBE-2016-033.
   Google Scholar
• Rietjens IM, Sotoca AM, Vervoort J, Louisse J. Mechanisms underlying the dualistic mode of action of major soy isoflavones in relation to cell proliferation and cancer risks. Mol Nutr Food Res. 2013;57:100–113.
   PubMed Web of Science ®Google Scholar
• Messina M. Soy and health update: evaluation of the clinical and epidemiologic literature. Nutrients. 2016;8:754.
   PubMed Web of Science ®Google Scholar
• Chen WF, Huang MH, Tzang CH, Yang M, Wong MS. Inhibitory actions of genistein in human breast cancer (MCF-7) cells. Biochim Biophys Acta. 2003;1638:187–196.
   PubMed Web of Science ®Google Scholar
• Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res. 1998;58:4851–4857.
   PubMed Web of Science ®Google Scholar
• Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev. 2010;29:465–482.
   PubMed Web of Science ®Google Scholar
• Hatkevich T, Ramos J, Santos-Sanchez I, Patel YM. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells. Exp Cell Res. 2014;327:331–339.
   PubMed Web of Science ®Google Scholar
• Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G, Shen L, et al. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget. 2015;6:44563–44578.
   PubMed Web of Science ®Google Scholar
• Zhou R, Xu L, Ye M, Liao M, Du H, Chen H. Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm Metab Res. 2014;46:753–760.
   PubMed Web of Science ®Google Scholar
• Diantini A, Subarnas A, Lestari K, Halimah E, Susilawati Y, et al. Kaempferol-3-O-rhamnoside isolated from the leaves of Schima wallichii Korth. inhibits MCF-7 breast cancer cell proliferation through activation of the caspase cascade pathway. Oncol Lett. 2012;3:1069–1072.
   PubMed Web of Science ®Google Scholar
• Phromnoi K, Yodkeeree S, Anuchapreeda S, Limtrakul P. Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids. Acta Pharmacol Sin. 2009;30:1169–1176.
   PubMed Web of Science ®Google Scholar
• Cook MT, Liang Y, Besch-Williford C, Hyder SM. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer. 2017;9:9–19.
   PubMed Web of Science ®Google Scholar
• Lin D, Kuang G, Wan J, Zhang X, Li H, Gong X, Li H. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. Oncol Rep. 2017;37:895–902.
   PubMed Web of Science ®Google Scholar